

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A05/2014

DESPATCHED ON 3RD JUNE 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A68; B44, -; Cw5, -; DR1, DR4; DQ5, DQ8

Summary of Results					Summary of Results				
Total tested	22	21	22	22	18	18	18	18	
Positive	2	11	2	11	0	1	0	3	
Negative	20	10	20	11	18	17	18	15	
Not Tested	1	1	1	1	1	1	1	1	
% Positive	9.1%	52.4%	9.1%	50.0%	0.0%	5.6%	0.0%	16.7%	
% Negative	90.9%	47.6%	90.9%	50.0%	100.0%	94.4%	100.0%	83.3%	
Consensus	Negative	Not Assessed	Negative	Not Assessed	Negative	Negative	Negative	Negative	
HLA Antibody (Defined By CDC)	B51	B17	A24	Cw4, Cw6					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	Samples NT due to staff shortages
11	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	
12	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
14	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	
15	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
23	Negative	Negative	Negative	Negative					
24	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
25	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
34	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
35	Negative	Equivocal	Negative	Negative	Negative	Negative	Negative	Negative	
38	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
39	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
41	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
42	Negative	Weak Positive	Negative	Weak Positive	Negative	Negative	Negative	Negative	
45	Positive	Positive	Positive	Positive	Negative	Negative	Negative	Positive	
48	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
51	Negative	Positive	Negative	Negative					
54	Positive	Positive	Positive	Positive					
58	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	
62	Negative	Positive	Negative	Positive					

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 15TH JULY 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

PBL/T-CELL CROSSMATCHING RESULTS OF SAMPLE 2A05/2014

DESPATCHED ON 3RD JUNE 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Cells used		Cell viability %		Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength			PBL	T-cells	PBL	T-cells		pre C'	post C'	
9	0	2	0	2	0	0	0	0	04-Jun	05-Jun	Yes	Yes	90	Cedarlane	30	30	AO/PI	
11		2-4							04-Jun	05-Jun	Yes	Yes	90		45	90	Fluoroquencher	
12	5%	10%	5%	5%	5%	5%	5%	5%	04-Jun	04-Jun	Yes	No	95	Cedarlane	30	90	EB/AO	
14	0	0	0	4	0	0	0	2	04-Jun	04-Jun	Yes	Yes	90	Cedarlane	60	120	EB/AO	
15	0	0	0	0	0	0	0	0	05-Jun	06-Jun	Yes	No	95	Cedarlane	60	60	Fluoroquencher EB/AO	
19	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	
20	1	2	1	3	1	1	1	1	04-Jun	05-Jun	Yes	No	95	Cedarlane	30	120	EB/AO	
23	1	1	1	1					04-Jun	04-Jun		Yes	90	Cedarlane	40	40	EB/AO	
24	20	40	20	80	20	30	20	50	04-Jun	05-Jun		Yes	90	Cedarlane	45	90	Fluoroquencher EB/AO	
25	1	1	1	1	1	1	1	1	05-Jun	05-Jun		Yes	99	Cedarlane	45	60	Fluoroquencher	
28	1	1	1	1	1	1	1	1	04-Jun	04-Jun		Yes	99	Cedarlane	30	45	EB/AO	
34	-	6	-	4	-	-	-	-	04-Jun	04-Jun		Yes	95	Cedarlane	30	90	EB/AO	
35	1	2	1	1	1	1	1	1	04-Jun	05-Jun	Yes	Yes	90	80	Cedarlane	45	90	Fluoroquencher
38	1	2	1	2	1	1	1	1	04-Jun	04-Jun	Yes	Yes	95	90	Cedarlane	60	60	EB/AO
39	-	-	-	-	-	-	-	-	04-Jun	04-Jun	Yes	No	95	Cedarlane	45	90	EB/AO	
41	0	0	0	0	0	0	0	0	04-Jun	04-Jun	Yes		100	Cedarlane	60	60	EB/AO	
42	-	20%	-	20-40%	-	-	-	-	04-Jun	04-Jun	Yes	No	95	TCS Biosciences	60	120	EB/AO	
45	4	6	4	4	1	1	1	2	04-Jun	05-Jun		Yes	99	Cedarlane	60	90	EB/AO	
48	-	-	-	-	-	-	-	-	04-Jun	04-Jun	Yes	No	90	Cedarlane	30	60	Eosin/EB	
51	0%	20-80%	0%	0%					04-Jun	05-Jun		Yes	95	Cedarlane	60	60	Fluoroquencher	
54	30%	30%	30%	20%					04-Jun	05-Jun		Yes	95	Cedarlane	60	60	PI	
58	5%	5%	5%	90%	5%	5%	5%	5%	04-Jun	04-Jun		Yes	95	Cedarlane	60	90	Fluoroquencher	
62	1	4	1	4					05-Jun	05-Jun		Yes	95	Cedarlane	60	120	EB/AO	

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A05/2014

DESPATCHED ON 3RD JUNE 2014

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A68; B44, -; Cw5, -; DR1, DR4; DQ5, DQ8

Summary of Results					Summary of Results				
Total tested	20	20	20	20	16	16	16	16	
Positive	3	20	2	19	0	3	0	8	
Negative	17	0	18	1	16	13	16	8	
Not Tested	1	1	1	1	1	1	1	1	
% Positive	15.0%	100.0%	10.0%	95.0%	0.0%	18.8%	0.0%	50.0%	
% Negative	85.0%	0.0%	90.0%	5.0%	100.0%	81.3%	100.0%	50.0%	
Consensus	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Not Assessed	
HLA Antibody (Defined By CDC)	B51	B17	A24	Cw4, Cw6					
Lab No.	Without DTT				With DTT (Not assessed)				Comments
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	Samples NT due to staff shortages
11	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	
12	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
14	Negative	Positive	Positive	Positive	Negative	Positive	Negative	Positive	
15	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	
19	NT	NT	NT	NT	NT	NT	NT	NT	
20	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
23	Negative	Positive	Negative	Positive					
24	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
25	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	
28	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
34	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
38	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	
39	Positive	Positive	Negative	Positive	Negative	Negative	Negative	Positive	
41	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	
42	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
45	Positive	Positive	Positive	Positive	Negative	Negative	Negative	Positive	
51	Negative	Positive	Negative	Positive					
54	Negative	Positive	Negative	Positive					
58	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
62	Negative	Positive	Negative	Positive					

PLEASE NOTE: THE NEXT DISTRIBUTION IS ON 15TH JULY 2014

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

UK NEQAS FOR H&I SCHEME 2A - CYTOTOXIC CROSSMATCHING

B-CELL CROSSMATCHING RESULTS OF SAMPLE 2A05/2014

DESPATCHED ON 3RD JUNE 2014

Lab No.	Without DTT				With DTT (Not assessed)				Date received	Date tested	Immunobeaded cells used	B-cell viability %	Complement manufacturer	Incubation Times		Visualisation of dead cells
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength						pre C'	post C'	
9	0	4	0	4	0	0	0	0	04-Jun	05-Jun	Yes	90	Cedarlane	30	30	AO/PI
11		4-6		4-6				4-6	04-Jun	05-Jun	Yes	90		45	90	Fluoroquen
12	20%	90%	20%	90%	20%	10%	10%	10%	04-Jun	04-Jun	Yes	80	Cedarlane	30	60	EB/AO
14	0	8	2	8	0	2	0	6	04-Jun	04-Jun	Yes	80	Cedarlane	60	120	EB/AO
15	0	8	0	4	0	0	0	2	04-Jun	05-Jun	Yes	95	Cedarlane	60	60	Fluoroquen EB/AO
19	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
20	1	9	1	4	1	1	1	1	04-Jun	05-Jun	Yes	95	Cedarlane	30	60	EB/AO
23	1	8	1	8					04-Jun	04-Jun	Yes	90	Cedarlane	40	40	EB/AO
24	30	50	30	70	20	60	30	50	04-Jun	05-Jun	Yes	80	Cedarlane	45	90	Fluoroquen EB/AO
25	1	4	1	1	1	1	1	1	05-Jun	05-Jun	Yes	99	Cedarlane	45	60	Fluoroquen
28	1	6	1	8	1	1	1	1	04-Jun	04-Jun	Yes	90	Cedarlane	30	45	EB/AO
34	6	8	-	8	-	-	-	-	04-Jun	04-Jun	Yes	90	Cedarlane	30	90	EB/AO
38	1	6	1	8	1	1	1	4	04-Jun	04-Jun	Yes	80	Cedarlane	60	60	EB/AO
39	2	6	-	6	-	-	-	2	04-Jun	04-Jun	Yes	95	Cedarlane	45	90	EB/AO
41	0%	50%	20%	80%	0%	50%	20%	80%	04-Jun	04-Jun	Yes	90	Cedarlane	45	45	EB/AO
42	-	60-80%	-	40-60%	-	-	-	-	04-Jun	04-Jun	Yes	90	TCS Biosciences	60	60	EB/AO
45	2	8	4	8	1	1	1	2/4	04-Jun	05-Jun	Yes	90	Cedarlane	30	75	EB/AO
51	0%	40-100%	0%	20-80%					04-Jun	05-Jun	Yes	90	Cedarlane	60	60	Fluoroquen
54	10%	60%	10%	40%					04-Jun	05-Jun	Yes	90	Cedarlane	60	60	PI
58	5%	95%	5%	100%	5%	5%	5%	5%	04-Jun	04-Jun	Yes	95	Cedarlane	60	90	Fluoroquen
62	1	8	1	8					05-Jun	05-Jun	Yes	95	Cedarlane	60	120	EB/AO

© Copyright Notice: Reports are confidential, and no data may be published without permission from UK NEQAS for H&I

EB - ethidium bromide
AO - acridine orange
PI - propidium iodide
Hb - haemoglobin
CFDA - carboxy-fluorescein diacetate